Interplay between mutant DNMT3A and UBA1 worsens survival through altered inflammatory and metabolic pathways
Jenna Fernandez(Mayo Clinic), Mrinal M. Patnaik(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), Matthew J. Koster(Mayo Clinic in Arizona), Rong He(Mayo Clinic), Aubrey Pinteric(TOCA at Banner Health), Jérôme Hadjadj(Sorbonne Université), Horatiu Olteanu(Mayo Clinic in Arizona), Kenneth J. Warrington(Mayo Clinic), Emma M. Groarke(MACOM (United States)), David B. Beck(Center for Human Genetics), Yael Kusne(WinnMed), Neal S. Young(National Heart Lung and Blood Institute), Pankaj Pradeep(Mayo Clinic), Christy M. Finke(Mayo Clinic), Kaaren K. Reichard(Mayo Clinic), Bhavisha A. Patel(MACOM (United States)), Fernanda Gutierrez‐Rodrigues(National Heart Lung and Blood Institute), Maria Sirenko(Center for Human Genetics), Megan M. Sullivan(Mayo Clinic in Arizona), Kambiz Kalantari(Mayo Clinic), Naseema Gangat(Mayo Clinic in Arizona), David S. Viswanatha(Mayo Clinic), Terra L. Lasho(Mayo Clinic)
Cited by 0
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Mutations in <i>TERT,</i> the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia
|New England Journal of Medicine|2005|717